Rufigallol attenuates splenic damage caused by STZ by targeting oxidative stress, inflammation, and the apoptosis pathway
Rufigallol attenuated STZ-induced splenic injury by reducing oxidative stress, suppressing inflammatory responses, and normalizing apoptotic markers (Bax, Bcl-2, and caspase-3), thereby preserving splenic structure and function in diabetic rats.